1-4 of 4
Kiyoshi Okamoto
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama, Yukiko Miyajima, Masaki Mikamoto, Takayuki Nakagawa, Hiroko Kuramochi, Setsuo Funasaka, Satoshi Nagao, Naoko Hata Sugi, Kiyoshi Okamoto, Yukinori Minoshima, Yusuke Nakatani, Yuki Karoji, Isao Ohashi, Yoshinobu Yamane, Toshimi Okada, Tomohiro Matsushima, Junji Matsui, Masao Iwata, Toshimitsu Uenaka, Akihiko Tsuruoka
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2016) 15 (11): 2630–2639.
https://doi.org/10.1158/1535-7163.MCT-16-0261
Published: 01 November 2016
View articletitled, E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Open the PDF for E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors

Yu Kato, Kimiyo Tabata, Yusaku Hori, Sho Tachino, Kiyoshi Okamoto, Junji Matsui
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A92.
https://doi.org/10.1158/1535-7163.TARG-15-A92
Published: 01 December 2015
View articletitled, Abstract A92: Effects of lenvatinib on tumor-associated macrophages enhance antitumor activity of PD-1 signal inhibitors
Journal Articles

Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model

Yusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, Kazuma Takase, Yukinori Minoshima, Kotaro Kodama, Masao Iwata, Norimasa Miyamoto, Kohei Sawada
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (4): 823–832.
https://doi.org/10.1158/1535-7163.MCT-13-0667
Published: 06 April 2014
View articletitled, Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model
Open the PDF for Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model in another window
Includes: Supplementary data
Journal Articles

Abstract A289: Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation.

Yusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada, Kazuma Takase, Yukinori Minoshima, Kotaro Kodama, Masao Iwata
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A289.
https://doi.org/10.1158/1535-7163.TARG-13-A289
Published: 01 November 2013
View articletitled, Abstract A289: Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation.